STOCK TITAN

Heartbeam Inc - BEAT STOCK NEWS

Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.

HeartBeam Inc (BEAT) pioneers portable cardiac monitoring solutions through its credit card-sized ECG device and AI-driven diagnostic platform. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in remote cardiology technology.

Access authoritative reporting on regulatory milestones, clinical study results, and strategic partnerships shaping the future of telehealth diagnostics. Our curated collection includes earnings reports, product launch announcements, and peer-reviewed research validations, including studies conducted with Harvard Medical School faculty.

Key updates cover developments in Vector ECG technology, FDA clearance progress, and AI algorithm enhancements that improve cardiac event detection accuracy. Bookmark this page to stay informed about innovations bridging hospital-grade diagnostics with at-home healthcare solutions.

Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) will conduct a conference call on March 24, 2022, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year results for fiscal 2021, ending December 31, 2021. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. A press release with results will precede the call. Interested parties can join via phone or webcast. A telephone replay will be available until June 24, 2022. HeartBeam focuses on innovative ECG technology for heart attack detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
conferences
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has announced a Business Associate Agreement and Clinical Trial Agreement with Phoebe Putney Health System to conduct a pilot study of HeartBeam’s Myocardial Infarction software product. This partnership aims to evaluate the software’s effectiveness in detecting heart attacks in emergency settings. HeartBeam will conduct additional studies and pursue future scientific and commercial collaborations, enhancing its position in the telehealth space for remote heart attack detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
partnership
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has announced a partnership with LIVMOR Inc. to develop a HeartBeam branded version of LIVMOR's FDA-cleared Halo+ Remote Patient Monitoring (RPM) platform. This collaboration aims to enhance heart attack detection by customizing the platform for HeartBeam's products. CEO Branislav Vajdic emphasized that using LIVMOR's established platform will expedite the FDA submission of their heart attack detection software, aimed at Emergency Department settings, later this year. This partnership aims to improve the accuracy of myocardial infarction detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
partnership
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has established a Scientific Advisory Board (SAB) to enhance its medical studies and product development. The board will be chaired by C. Michael Gibson, an esteemed cardiologist known for his work in cardiovascular research. Dr. Gibson's extensive experience includes leading over 120 clinical trials and contributing to major cardiac drug approvals. This strategic move aims to bolster HeartBeam's proprietary ECG telemedicine technology, focusing on accurate heart attack diagnosis in ambulatory settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
management
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare company, announced its participation in the H.C. Wainwright BIOCONNECT Conference from January 10-13, 2022. Key executives, including CEO Branislav Vajdic, will conduct video meetings during the event. The conference aims to showcase HeartBeam's innovative ECG telemedicine technology, designed to diagnose cardiovascular diseases effectively outside traditional medical settings. This breakthrough technology targets a significant market need, particularly in diagnosing heart attacks in high-risk patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has appointed Alan Baumel as the new Chief Operating Officer, a role focused on product development and regulatory affairs for their innovative ECG telemedicine technology. With over 35 years in the medical device sector, Baumel is expected to enhance HeartBeam's commercialization strategy and accelerate FDA product development. His experience includes leadership roles at Bardy Diagnostics and contributions to improving medical device quality and safety. HeartBeam aims to address significant needs in heart attack detection outside medical institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
management
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed a $16.5 million IPO, selling 2,750,000 units at $6.00 each. The IPO generated net proceeds of $14.9 million, boosting the company’s cash balance to approximately $15.7 million. HeartBeam aims to advance its FDA-ready telemedicine solutions for cardiovascular assessment, with significant milestones set for 2022 and 2023. Q3 2021 financial results show an increased net loss of $1.2 million, up from $335,000 in Q3 2020, while R&D expenses rose to $105,000 from $57,000 year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.94%
Tags
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed its initial public offering of 2,750,000 units at $6.00 each, generating net proceeds of $14.9 million. Each unit comprises one share of common stock and one five-year warrant to purchase a share at the same price. The common stock and warrants are now trading on the Nasdaq Capital Market under the symbols 'BEAT' and 'BEATW', respectively. This funding will help advance HeartBeam's proprietary ECG telemedicine technology aimed at improving cardiovascular disease diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has priced its initial public offering of 2,750,000 units at $6.00 per unit, consisting of one share of common stock and one warrant. The offering is expected to generate $16.5 million in gross proceeds, aimed at funding product development and regulatory work for its ECG telemedicine technology. The company anticipates trading to begin on November 11, 2021, with a closing date set for November 15, 2021. The underwriters have a 30-day option to purchase additional shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary

Philips has announced its acquisition of BioTelemetry for USD 72.00 per share, totaling an implied enterprise value of USD 2.8 billion. This acquisition aligns with Philips' strategy to enhance healthcare delivery by combining its hospital monitoring capabilities with BioTelemetry’s strengths in remote cardiac diagnostics. BioTelemetry, which reported USD 439 million in sales in 2019, monitors over 1 million cardiac patients annually. The deal is anticipated to yield significant synergies and is expected to be accretive to Philips’ sales growth and adjusted EBITA margin beginning in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Heartbeam Inc

Nasdaq:BEAT

BEAT Rankings

BEAT Stock Data

54.79M
26.15M
23.17%
7.89%
0.68%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA